Since mid-2022, the macro acquisition environment has faced the challenges of inflation and increasing interest rates, among a variety of other headwinds. Global deal flow is down from its 2021 peak. Yet, as this white paper will explain at a granular level, private equity investment in healthcare companies remains a viable and, in some cases, thriving asset class in relation to other target industries.
Expect private equity backed healthcare investing to remain active (relative to the field) during this time of economic uncertainty. If and when the macroeconomic headwinds clear, investments in the healthcare sector should be well-positioned for successful exit opportunities.
Please see full publication below for more information.
